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the cessation of IL-4 or IFN-g signaling in vivo (Starr et
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ported that IFN-g-deficient SOCS-1 KO mice are free
Suppressor of cytokine signaling-1 (SOCS-1), also from these severe pathological changes (Alexander et
known as STAT-induced STAT inhibitor-1 (SSI-1), is a al., 1999; Marine et al., 1999), indicating that SOCS-1
negative feedback molecule for cytokine signaling, indeed negatively regulates overshooting of IFN-g sig-
and its in vivo deletion induces fulminant hepatitis. naling. This study provided a new insight into the essen-
However, elimination of the STAT1 or STAT6 gene or tial role of the IFN-g/SOCS-1 system in the development
deletion of NKT cells substantially prevented severe and maintenance of the immune system. However, they
hepatitis in SOCS-1-deficient mice, while administra-
do not seem to imply that the lethal changes in SOCS-1
tion of IFN-g and IL-4 accelerated its development.
KO mice are solely attributable to oversignaling of IFN-g,
SOCS-1 deficiency not only sustained IFN-g/IL-4 sig-
because SOCS-1 also negatively regulates various kinds
naling but also eliminated the cross-inhibitory action
of signalings (Naka et al., 1997, 1998; Sakamoto et al.,of IFN-g on IL-4 signaling. These results suggest that
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in inhibiting STAT6 activation in vitro (Dickensheets et
al., 1999; Venkataraman, et al., 1999). Thus, withoutIntroduction
cross-talk inhibition via SOCS-1, IL-4 and IFN-g signal-
ings might be independently, occasionally at the sameMost hematopoietic cells are exposed to various cyto-
time, and persistently transduced to abnormally activatekines and are systematically regulated by a complicated
lymphocytes, causing injuries of immune organs andnetwork of cytokines. Signaling through Janus kinase
liver. It is therefore important to determine whether(JAK)/signal transducers and activators of transcription
SOCS-1 deficiency induces pathological changes by(STAT) pathway is one of the most important signal path-
abolishing a cross-talk inhibition of IFN-g and IL-4 sig-ways activated immediately after cytokine stimulation
nalings or simply by amplifying one signal. In this study,(for a review, see Darnell et al., 1994; Kishimoto et al.,
we first tested whether deletion of the STAT1 gene in-1994; Ihle, 1995). Suppressor of cytokine signaling-1
stead of the IFN-g gene results in similar prevention of(SOCS-1), also known as STAT-induced STAT inhibi-
fulminant hepatitis in SOCS-1 KO mice. Second, wetor-1 (SSI-1), is an intracellular protein that inhibits JAK-
analyzed whether deletion of the STAT6 gene also pre-mediated cytokine signaling by binding to JAKs (Starr
vents these pathological changes, as we wished to clar-et al., 1997; Endo et al., 1997; Naka et al., 1997; for a
ify whether SOCS-1 deficiency facilitates simultaneousreview, see Naka et al., 1999; Krebs and Hilton, 2000;
overshooting of IL-4, which, in combination with IFN-gChen et al., 2000; Nicola and Greenhalgh, 2000; Yasu-
signaling, induces lethal pathologies. Lastly, we exam-kawa et al., 2000; Naka et al., 2001; Starr, 2001). Although
SOCS-1 can be induced by various cytokines, such as ined whether SOCS-1 in hepatic NKT cells acts as a
interferon (IFN)-g, interleukin (IL)-4, IL-2, and IL-6, the pivotal regulating factor that limits their hepatocyte-kill-
target molecules of SOCS-1 among members of the JAK ing action. This is the first in vivo study to show that
family have not been precisely identified yet (Starr et SOCS-1 is a critical molecule for cross-talk inhibition of
IFN-g and IL-4 signalings, resulting in suppression of
the overactivation of hepatocytotoxic NKT cells.5Correspondence: naka@imed3.med.osaka-u.ac.jp
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Figure 1. Disruption of STAT1 or STAT6 Prevents Perinatal Death of SOCS-1 KO Mice
Mice with various gene mutations were kept under SPF conditions. Survival rate (A) and body weight (B) were measured until 90 and 35 days
after birth, respectively. Two weeks after birth, thymus and liver were sampled from various types of mice, and the ratios of the weight of
these organs to body weight were calculated (C). Data in (A) are data of 20 mice in each experimental group and are representative of two
independent experiments with similar results. Data in (B) and (C) show mean 6 SD for five mice from each group and are representative of
three independent experiments with similar results.
Results had been achieved in the livers of both types of DKO
mice (Figure 2C). SOCS-1 KO mice showed fulminant
hepatitis characterized by severe fatty degeneration andSTAT1 or STAT6 Deficiency Protects SOCS-1 KO
Mice from Various Kinds of Abnormalities necrosis with massive lymphocyte infiltration (Starr et
al., 1998; Naka et al., 1998; Alexander et al., 1999). InWe generated SOCS-1 KO mice lacking STAT1 (SOCS-
1/STAT1 DKO mice) or SOCS-1 KO mice lacking STAT6 contrast, the livers from SOCS-1/STAT1 DKO mice like
those from SOCS-1/IFN-g DKO mice (Alexander et al.,(SOCS-1/STAT6 DKO mice) by deletion of the STAT1 or
STAT6 gene in SOCS-1 KO mice. All the SOCS-1 KO 1999; Marine et al., 1999) remained almost intact except
for infiltration by a small number of lymphocytes (Figuremice died within 3 weeks after birth. In contrast, mor-
tality was significantly reduced in SOCS-1/STAT1 or 2C), thus confirming the pathological role of IFN-g in
this liver injury. To our surprise, SOCS-1/STAT6 DKOSOCS-1/STAT6 DKO mice (Figure 1A). As also pre-
viously reported (Starr et al., 1998; Naka et al., 1998), mice also had almost intact liver tissue, which suggests
that SOCS-1 might prevent development of fulminantSOCS-1 KO mice showed a marked growth retardation,
while SOCS-1/STAT1 and SOCS-1/STAT6 DKO mice hepatitis by inhibiting of simultaneous transduction of
both IFN-g and IL-4 signals.grew larger than SOCS-1 KO mice but were still smaller
than wild-type (WT) mice (Figure 1B). Moreover, severe
thymic atrophy was partly improved, and hepatomegaly
was almost completely eliminated in SOCS-1/STAT1 Relevant Role of SOCS-1-Deficient Lymphocytes
in Severe Hepatitis Observed in SOCS-1 KO Miceand SOCS-1/STAT6 DKO mice (Figure 1C).
Elimination of either STAT1 or STAT6 led to improve- As SOCS-1 is strongly expressed in lymphoid organs,
especially in T cells (Starr et al., 1997; Naka et al., 1997;ment in pathological changes in various organs of
SOCS-1 KO mice. Histological findings and determina- Marine et al., 1999), we compared the proportions of
splenic T cells expressing CD69, an activation marker,tion of the numbers of various cells on day 10 after birth
revealed that thymic atrophy had partly improved in among mice with various genetic mutations. SOCS-1 KO
mice showed an increase in the population of activated TSOCS-1/STAT1 or SOCS-1/STAT6 DKO mice (Figures
2A and 2B),and that complete histological restoration cells, while SOCS-1/STAT1 or SOCS-1/STAT6 DKO mice
SOCS-1/SSI-1 as a Cross-Talk Inhibitor
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Figure 2. Improvement of Tissue Anomalies in SOCS-1 KO Mice by Elimination of STAT1 or STAT6
Thymus (A and B) and liver (C) were sampled from mice with various genotypes 2 weeks after birth for histological study (A and C) and cell
count (B). Thymocytes were isolated, and the cells were counted (B). (A) Hematoxylin/eosin (HE) staining, original magnification: 325. (C) HE
staining (left four panels) and Sudan III staining (right four panels), original magnification: 380. Data in (A) and (C) are representative of 10
independent experiments with similar results. Data in (B) show mean 6 SD of five mice from each group and are representative of five
independent experiments with similar results.
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Figure 3. Disruption of STAT1 or STAT6 Re-
stores Spontaneously Overactivated T Cells
in SOCS-1 KO Mice
Splenic CD41 cells (left panel) or CD81 cells
(right panel) were isolated from mice with var-
ious genotypes by MACS. The proportion of
CD69 expression for each cell group was
measured by FACS. Data are representative
of 10 independent experiments with similar
results.
contained a reduced but still higher proportion of spon- Since RAG2-deficient SOCS-1 KO mice avoid severe
liver injury (Marine et al., 1999), NK cells seem to betaneously activated T cells in their spleen when com-
pared with, respectively, the spleens from SOCS-1 KO insignificant as hepatocytotoxic effector cells. As the
liver has a unique immune system characterized by theand WT mice (Figure 3).
Next, we investigated the cellular mechanism underly- presence of abundant NKT cells, a potent cytotoxic cell
population (Kawamura et al., 1998), we focused on theing the pathological changes in SOCS-1 KO mice, with
special attention to severe liver injuries. To clarify role of hepatic NKT cells in this liver injury. Hepatic
lymphocytes from SOCS-1 KO mice killed hepatocyteswhether these lethal alterations are due to abnormalities
in lymphocytes, in stromal cells sustaining lymphocyte from syngeneic WT mice in a perforin-dependent but
Fas/Fas ligand (Fas L)-independent manner (Figure 5A).maturation, or in parenchymal cells, we transferred he-
matopoietic progenitor cells from the SOCS-1 KO fetal The hepatocytotoxicity of SOCS-1-deficient hepatic
lymphocytes was reduced after the deletion of NK1.11livers (E16.5 days) into RAG2-deficient (RAG2 KO) mice.
All the RAG2 KO mice reconstituted with SOCS-1-defi- cells consisting of NK cells and NKT cells (Figure 5B).
NK cells and NKT cells show different susceptibilitiescient lymphocytes died within 7 weeks after transplan-
tation, while RAG2 KO mice reconstituted with WT to in vivo treatment with anti-asialo GM1, possibly due
to the difference in their expression of asialo GM1 (So-lymphocytes survived normally. Furthermore, SOCS-1-
deficient chimeric mice showed various characteristics noda, et al., 1999). By taking advantage of this differ-
ence, we could selectively deplete NK cells without af-similar to those of SOCS-1 KO mice, such as relative
weight loss in the thymus and spleen and relative weight fecting NKT cells (Figure 5C-2). This treatment did not
eliminate the hepatocytotoxicity of SOCS-1-deficientgain in the liver (Figure 4A). Indeed, histological findings
for various tissues from SOCS-1-deficient chimeric mice hepatic lymphocytes (Figure 5C-1). These results sug-
gest that NKT cells may belong to the effector cell popu-obtained 6 weeks after transplantation revealed disap-
pearance of the thymic cortex (data not shown) and lations killing hepatocytes. In fact, SOCS-1 was induced
in WT NKT cells upon stimulation with IFN-g (data notsevere liver injuries (Figure 4B). Moreover, the critical
involvement of SOCS-1-deficient lymphocytes in the in- shown), and the number of NKT cells (CD3/NK1.1 double
positive cells) was markedly elevated in the liver ofduction of these pathological changes is well docu-
mented by a recent study in which SOCS-1-deficient SOCS-1 KO mice compared with that of WT mice (Figure
5D). Furthermore, more than 65% of SOCS-1-deficientbone marrow cells, when used to reconstitute Jak3-
deficient mice lacking T cells, B cells, and NK cells, NKT cells in the liver spontaneously expressed CD69,
while only less than 20% of WT hepatic NKT cells didreplicated the phenotype seen in SOCS-1-deficient mice
(Marine et al., 1999). In contrast, RAG2-deficient SOCS-1 so (Figure 5E). In contrast, both SOCS-1/STAT1 and
SOCS-1/STAT6 DKO mice contained comparable num-KO mice that lacked T cells and B cells but contained
NK cells showed healthy growth (Marine et al., 1999). ber of NKT cells and similar levels of their CD69 expres-
sion in their livers as compared to WT mice (data notThese findings in combination with our results presented
here strongly indicate that abnormal lymphocytes cause shown).
To investigate whether SOCS-1-deficient NKT cellsthe multiple pathological changes in SOCS-1 KO mice.
have the potential to cause such severe liver injury in
vivo, we administered a-galactoceramide (a-GalCer), aSpontaneously Activated Hepatic NKT Cells Cause
Liver Injuries in SOCS-1 KO Mice selective activator of NKT cells to pre-onset SOCS-1
KO mice. As shown in Figure 5F, SOCS-1 KO mice butNext, we identified the cell types and effector molecules
responsible for severe liver injuries in SOCS-1 KO mice. not WT mice suffered from fulminant hepatitis 12 hr
SOCS-1/SSI-1 as a Cross-Talk Inhibitor
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Figure 4. RAG2 KO Mice Reconstituted with SOCS-1-Deficient Lymphocytes Spontaneously Develop Fulminant Hepatitis
(A) RAG2 KO mice were reconstituted with fetal liver stem cells from SOCS-1 KO (SOCS-12/2 in RAG22/2) or WT mice (SOCS-11/1 in RAG22/2).
Six weeks after reconstitution, thymus, spleen, and liver were sampled to measure their weight, and the ratios of the weight of these organs
to body weight were calculated. Data show mean 6 SD of 10 mice in each group and are representative of three independent experiments
with similar results.
(B) Six weeks after reconstitution, liver was sampled for histological study. HE staining, original magnification: 3 80. Data are representative
of five independent experiments with similar results.
after the a-GalCer challenge (Figure 6). Thus, SOCS-1- that a-GalCer reactive SOCS-1-deficient T cells solely
mediate the hepatic pathological changes in SOCS-1deficient NKT cells that are highly susceptible to the
stimulation with a-GalCer might have the capacity to KO mice. These results suggest that liver injuries ob-
served in SOCS-1 KO mice might be due to the anoma-cause severe liver injury upon the appropriate stimuli,
including cytokines, in vivo, although it is still elusive lously activated NKT cells.
Immunity
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Figure 5. Hepatocytotoxicity of Hepatic NKT Cells in SOCS-1 KO Mice
(A) Hepatic lymphocytes were isolated from WT or SOCS-1 KO mice and were incubated with 100 nM concanamycin A (CMA) or 20 mg/ml of
anti-murine Fas L for 1 hr, and their hepatocytotoxicity was determined by 4 h-[51Cr] release assay.
(B) NK1.11 cells were removed from hepatic lymphocytes by MACS and their hepatocytotoxicity was determined.
(C-1) Hepatic lymphocytes were treated twice with anti-asialo GM1 and complement for depletion of NK cells, and their hepatocytotoxicity
was determined. (C-2) Surface phenotypes of the cells before and after the treatment were determined by FACS.
(D) Hepatic lymphocytes from WT or SOCS-1 KO mice were incubated with biotinylated anti-NK1.1 followed by Cy-streptavidin and FITC-
conjugated anti-CD3, and the NKT cell proportion (NK1.11CD31 cell population) was calculated.
(E) Hepatic lymphocytes were incubated with biotinylated anti-NK1.1 followed by Cy-streptavidin, FITC-conjugated anti-CD3, and PE-conju-
gated anti-CD69. The proportion of CD691 cells gated on NK1.11CD31 cells was calculated. Data show mean 6 SD of triplicate and are
representative of three independent experiments with similar results (A, B, and C-1). Data are representative of five independent experiments
with similar results (C-2, D, and E).
Involvement of Simultaneous Signaling of IFN-g/IL-4 because of the difficulty in obtaining a sufficient number
of NKT cells from WT livers. Although we performed thein NKT Cells in Severe Liver Injuries
As previously reported, treatment of thymocytes from reverse procedure, we could not obtain the same results
(data not shown). These results suggest that SOCS-1SOCS-1 KO mice with IL-4 resulted in long-term tyrosine
phosphorylation of STAT6, indicating that SOCS-1 can induced by IL-4 might be insufficient to inhibit STAT1
phosphorylation and/or signaling suppressor(s) otherinhibit STAT6 tyrosine phosphorylation in vivo (Naka et
al., 1998). This is also the case for STAT1 signaling. As than SOCS-1 might negatively regulate the IL-4-induced
inhibition of STAT1 phosphorylation.shown in Figure 7A, tyrosine phosphorylation of STAT1
was abnormally extended in SOCS-1-deficient thymo- Finally, we investigated whether SOCS-1-deficient
NKT cells directly cause severe liver injury via dysregu-cytes as compared with WT (Figure 7A), indicating that
disruption of SOCS-1 sustains activation of both STAT1- lated signalings of IFN-g and IL-4. Pre-onset SOCS-1
KO mice administered with IFN-g and IL-4 resulted inand STAT6-mediated signalings.
Next, we investigated whether IFN-g-induced SOCS-1 severe liver injuries similar to those seen in onset SOCS-1
KO mice (Figure 7C). In contrast, NK/NKT cell-depletedis essential for negative regulation of IL-4 signaling as
well as its own signaling. To test this possibility, we pre-onset SOCS-1 KO mice were resistant to such treat-
ment (Figure 7C). Pre-onset SOCS-1 KO mice that hadcultured splenic T cells with IFN-g followed by stim-
ulation with IL-4 and determined the tyrosine phos- been pretreated with anti-asialo GM1 Ab lacked NK cells
but maintained NKT cells in their livers as in the resultsphorylation of STAT6. As shown in Figure 7B, IFN-g-pre-
stimulated SOCS-1-deficient T cells did show tyrosine of in vitro treatment shown in Figure 5C (unpublished
data). They remained sensitive to a challenge with IFN-gphosphorylation of STAT6 in response to IL-4, whereas
the subsequent stimulation did not induce STAT6 tyro- plus IL-4 (data not shown). Pre-onset SOCS-1 KO mice
did not suffer from severe liver injuries at 24 hr aftersine phosphorylation in WT T cells. An attempt to make
the same comparison by using hepatic NKT cells failed challenge with IFN-g or IL-4 alone (data not shown). All
SOCS-1/SSI-1 as a Cross-Talk Inhibitor
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Figure 6. a-GalCer Was Administered to Pre-Onset SSI-1 KO Mice or WT Mice
At 12 hr, the liver specimens were sampled for histological study. (HE staining, original magnification: 3 200) Data are representative of five
independent experiments with similar results.
these findings together suggest that SOCS-1 may play 1999; Narazaki et al., 1998; Yasukawa et al., 1999; Nich-
olson et al., 1999). Alternatively, SOCS-1 shows no spec-an essential role in regulating cytokine signalings in vivo
and that depletion of SOCS-1 may facilitate the concur- ificity for cytokines or JAKs (for a review, see Naka et
al., 1999; Krebs and Hilton., 2000; Chen et al., 2000;rent transmission of multiple cytokine signalings to pro-
duce abnormally activated T cells, including hepatic Nicola and Greenhalgh, 2000). In addition, a previous
study of ours demonstrated that SOCS-1 is capable ofNKT cells, thus leading to severe liver injuries.
inhibiting activation of STAT6 and the action of IL-4
in vivo (Naka et al., 1998). Moreover, various lesionsDiscussion
observed in SOCS-1 KO mice were eliminated not only
in SOCS-1/STAT1 DKO but also in SOCS-1/STAT6 DKOIFN-g-deficient SOCS-1 KO mice have been shown to
avoid various abnormalities observed in SOCS-1 KO mice (Figures 1 and 2). On the basis of these findings,
it can be assumed that SOCS-1 is a molecule actingmice (Alexander et al., 1999; Marine et al., 1999). This
result suggested the possibility that SOCS-1 might be downstream not only on IFN-g but also on other cyto-
kines, including IL-4 in vivo.a selective inhibitor of IFN-g signaling and that IFN-g is
principally responsible for inducing these pathological Our present data, that SOCS-1/STAT1 DKO avoided
liver injury (Figures 1 and 2), have further substantiatedchanges in vivo. However, previous studies have not
clarified the mechanisms by which SOCS-1 selectively the previous conclusion (Alexander et al., 1999; Marine
et al., 1999). To our surprise, however, deletion of theinhibits IFN-g signaling. Rather, many in vivo and in vitro
studies have demonstrated that SOCS-1 inhibits a wide STAT6 gene similarly prevented these pathological
changes (Figures 1 and 2). These results suggest thatrange of signalings of cytokines/hormones, including
IL-4, IL-6, IFN-g, thrombopoietin, leukemia inhibitory persistent activation of both STAT1 and STAT6, but
not of STAT1 alone, is responsible for inducing thesefactor, prolactin, insulin, growth hormone, and stem cell
factor (Starr et al., 1997; Naka et al., 1997; Losman et pathological changes. IFN-g and IL-4 were found to in-
hibit overactivation of STAT1 and STAT6 signalings, re-al., 1999; Adams et al., 1998; Hansen et al., 1999; Ram
and Waxman, 1999; Pezet et al., 1999; Tomic et al., 1999; spectively, via SOCS-1 (Figure 7A). Moreover, STAT1-
induced SOCS-1 inhibited STAT6 activation (Figure 7B).Sakamoto et al., 1998; Song and Shuai, 1998; Morita et
al., 2000; Kawazoe et al., 2001) and that SOCS-1 has Thus, IFN-g inhibits not only its own signal but also
IL-4 signals via SOCS-1. Deletion of the STAT1 gene inthe capacity to bind to all JAKs (Starr et al., 1997; Endo
et al., 1997; Naka et al., 1997; Fujimoto et al., 2000; SOCS-1 KO mice allows persistent activation of STAT6
but not of STAT1 and deletion of STAT6 gene vice versa,Losman et al., 1999; Helman et al., 1998; Pezet et al.,
Immunity
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Figure 7. Involvement of Dysregulated Cross-Talk Inhibition of IFN-g and IL-4 Signaling in SOCS-1-Deficient NKT Cells in Severe Hepatitis
(A) Thymocytes were incubated with IFN-g or IL-4, and their STAT1 and STAT6 phosphorylation was determined by means of immunoblotting
using anti-phosphorylated STAT1 and anti-phosphorylated STAT6, respectively.
(B) Splenic T cells were incubated with or without IFN-g followed by additional incubation with IL-4 for the indicated time. The phosphorylated
STAT1 and STAT6 were determined with the same procedure as shown in (A).
(C) SOCS-1 KO mice were administered with anti-NK1.1 mAb or control IgG, and 2 days later were challenged with IFN-g plus IL-4. At 24 hr,
the liver specimens were sampled for histological study. (HE staining, original magnification: 3 200). Data are representative of five independent
experiments with similar results.
resulting in avoiding severe pathological changes. Thus, of another signal pathway besides JAK/STAT signal
transduction in IFN-g signaling.activated STAT1 and STAT6, when collaborated in the
absence of SOCS-1, mediate severe liver injury. Trans- Concanavalin A (Con A)-induced hepatitis is a T cell-
mediated fulminant hepatitis model in mice (Tiegs et al.,genic mice overexpressing IFN-g or IL-4 in their lympho-
cytes or hepatocytes have been reported to display 1992; Lohr et al., 1994). Many factors are involved in
Con A-induced hepatitis. Since IFN-g-deficient mice arespontaneous thymic atrophy with relatively early death
although they remain entirely free of fulminant hepatitis resistant to Con A-induced hepatitis, and pretreatment
with neutralizing anti-IL-4 protects them against this(Lewis et al., 1991; Tepper et al., 1990; Erb et al., 1997;
Young et al., 1997; Toyonaga et al., 1994). These findings form of hepatitis, both IFN-g and IL-4 seem to be in-
volved in this liver injury (Kaneko et al., 2000; Tagawaand the results of our study suggest that thymic and
splenic changes observed in SOCS-1/STAT1 and SOCS- et al., 1997; Toyabe et al., 1997; Chen and Paul, 1997).
Furthermore, Va14- deficient mice lacking NKT cells are1/STAT6 DKO mice could be due to oversignaling of
residual, endogenous IL-4, and IFN-g, respectively. resistant to Con A hepatitis (Kaneko et al., 2000), which
suggests an essential role for NKT cells in this disease.However, the severe liver injuries seem to require the
participation in simultaneous signal transduction of mul- The liver contains a much higher proportion of NKT cells
than do other tissues. Moreover, NKT cells possess re-tiple cytokines, at least of both IFN-g and IL-4. Although
IFN-g-deficient SOCS-1 KO mice completely recovered ceptors for both IL-4 and IFN-g, so that they can receive
simultaneous signaling from both IFN-g and IL-4. It isfrom the complex disease observed in SOCS-1 KO mice
(Alexander et al., 1999; Marine et al., 1999), the STAT1- also known that the cytotoxicity of NKT cells is enhanced
by IL-12 (Kawamura et al., 1998) and IL-4 via upregula-deficient SOCS-1 KO mice in our study did not show
complete recovery in some organs, such as thymus and tion of their expression of FasL and Granzyme B (Ka-
neko, et al., 2000). As shown in our study, this is alsospleen. This discrepancy may be due to the involvement
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were treated with 10 mg/ml of IFN-g, 10 mg/ml of IL-4, or 10 mg/mlthe case for fulminant hepatitis in SOCS-1 KO mice.
of IFN-g followed by 10 mg/ml of IL-4 for the times indicated. TheSOCS-1-deficient hepatic lymphocytes were intrinsi-
cells were lysed with an NP-40 lysis buffer (20 mM Tris-HCl [pH 7.5],cally cytotoxic against syngeneic hepatocytes (Figure
150 mM NaCl, 1% NP-40, 10 mM Na2VO4, 0.5 mM dithiothreitol, 15) and lost their hepatocytotoxicity after deletion of NKT mg/ml Pepstatin A, 1 mg/ml Leupeptin, and 1 mM PMSF) and clarified
cells (Figure 5). Furthermore, in vivo deletion of NKT by centrifugation. The supernatants collected were subjected to an
8% SDS-PAGE. The proteins were transferred onto a nitrocellulosecells rescued pre-onset SOCS-1 KO mice from IFN-g
filter (Schleier & Schuell, Dassel, Germany). After blocking with 5%plus IL-4-induced liver injuries (Figure 7C), while control
skim milk, the filter was incubated with anti-phospho-specific STAT1IgG-administered pre-onset SOCS-1 KO mice suffered
or phospho-specific STAT6 Abs (New England Biolab, MA, USA),from liver injuries similar to those observed in onset
and then with the horseradish peroxidase-conjugated anti-rabbit
SOCS-1 KO mice after administration of IFN-g plus IL-4 IgG Ab. The signals were detected with an ECL system (Amersham,
(Figure 7C). Bukinghamshire, England). After the Abs had been stripped, the
filter was reprobed with anti-STAT1 (Transduction Labolatry, KY,We observed spontaneous development of fulminant
USA) or anti-STAT6 Abs (Santa Cruz, CA, USA).hepatitis in SOCS-1 KO mice. At present, we do not
know whether this change is induced intrinsically or
Assay for Hepatocytotoxicityextrinsically, but we succeeded in shortening the period
Hepatocytotoxicity was determined by the method described else-required for development of the lethal pathological
where with some modification (Tsutsui et al., 1992). In brief, liverchanges by administration of anti-CD3 (data not shown)
parenchymal cells (1 3 105/ml) prepared from WT C57BL/6 mice
or a-GalCer (Figure 6). Thus, we can assume that were incubated in a 96-well-collagen type I-coated plate overnight,
SOCS-1 KO mice may be hypersensitive to potentially washed twice with the culture medium kept at 378C, and labeled
contaminating pathogens even under SPF conditions. with [51Cr]-sodium chromate for 1 hr. Hepatic lymphocytes from
mice with various mutants were incubated with 20 mg/ml of anti-The study presented here demonstrated that IFN-g-
murine Fas L or 100 nM concanamycin A (Wako, Osaka, Japan) forinduced SOCS-1 is essential for the inhibition of IL-4
1 hr and incubated with the labeled liver parenchymal cells at varioussignaling in vivo and that the disturbance of this cross-
effector-target cell ratios for 4 hr. In some experiments, we depleted
talk inhibition abnormally activates NKT cells, particu- NK1.11 cells from hepatic lymphocytes by MACS after incubation
larly their hepatocytotoxic activity against self-driven with biotinylated anti-NK1.1 (PharMingen) followed by additional
cells, consequently leading to fulminant hepatitis. How- incubation with streptavidin-microbeads (Miltenyi Biotec). We also
depleted the NK cell population by incubating the cells twice withever, these results cannot exclude the possibility that
100 mg/ml of anti-asialo GM1 (Wako) plus complement for 30 min,other cells besides NKT cells are involved. SOCS-1/
followed by determination of their hepatocytotoxicity. Hepatocyto-CD1 double KO mice will be expected to provide direct
toxicity was calculated as previously reported (Tsutsui et al., 1992).
evidence of the essential role of NKT cells in liver injuries Spontaneous release of hepatocytes was less than 8% of their maxi-
of SOCS-1 KO mice. Our present study allows us to mum release.
investigate the possible involvement of SOCS-1 dys-
function in autoimmunity and infection-induced intracta- Depletion of NKT Cells and In Vivo Stimulation
ble organ failures. Further analysis of SOCS-1 might of IFN-g Plus IL-4
lead to new therapies even for cancer by focusing on Mice at 3 days after birth were injected intraperitoneally with 0.1 ml
PBS containing 2.5 mg anti-NK1.1 mAb (PK136). Two days afterstrengthening the cytotoxic action of NKT cells. We are
treatment with NK1.1 mAb, these mice were injected intraperitone-now clarifying how SOCS-1 takes part in cross-talk inhi-
ally with 0.1 ml PBS containing both 3 mg IFN-g and 1 mg IL-4.bition for other cytokines and what roles dysregulated
SOCS-1 plays in other tissue damage.
Administration of a-GalCer
Mice (3 days after birth) were injected intraperitoneally with 0.1 mlExperimental Procedures
PBS containing either 1 mg a-GalCer or control vehicle, which were
provided by KIRIN (Tokyo, Japan).Mice
STAT1 (Meraz et al., 1996), STAT6 (Takeda et al., 1996), and SOCS-1
KO mice (Naka et al., 1998) were established as previously de- Adoptive Transfer
scribed. All SOCS-1 KO mice were on the C57BL/6 background Recipient RAG2 KO mice, kindly provided by Dr. Itoh at CIEA (Kana-
(backcrossed more than seven generations). gawa, Japan), were irradiated with 700 rad. Donor cells from embry-
onic day 16.5 (E16.5) fetal liver of SOCS-1 KO or WT mice were
Cell Preparation and Cell Counts suspended in DMEM supplemented with 2% fetal calf serum (2 3
Single-cell suspensions were obtained from thymi and spleens after 107/ml). Recipient animals were injected i.v. with 2 3 106 donor cells.
the cells had been passed through mesh filters. Spleen cells were
also treated with Ack buffer (0.15 M NH4Cl, 1 mM KHCO3, and 0.1
AcknowledgmentsmM Na2EDTA) to lyse RBC. The total number of cells was determined
by microscopic observation of trypan blue-stained cells and using
We gratefully acknowledge the provision of STAT1 KO mice by Dr.hemocytometers
R.D. Schreiber at Washington University, STAT6 KO mice by Dr. S.
Akira at Osaka University (Osaka, Japan), RAG2 KO mice by Dr. M.Flow Cytometric Analysis
Itoh (CIEA, Kanagawa, Japan), and anti-murine Fas L mAb by Dr.Cells were stained with the following monoclonal Abs (mAbs): FITC-,
N. Kayagaki (Juntendo University, Tokyo, Japan). We thank Dr. S.PE-, or APC-conjugated anti-CD3e, anti-CD4, anti-CD8, anti-CD69,
Nagata (Osaka University) for helpful discussions, Dr. T. Hoshinoand anti-B220 (PharMingen, San Diego CA). Stained cells were ana-
(Kurume University, Kurume, Japan) for the kind gift of PK136, Ms.lyzed on a FACSCalibur (Becton Dickinson, San Jose, CA) using
K. Sato (KAC Corp, Shiga, Japan) for expert management of theCellQuest software (Becton Dickinson). Live lymphocytes were
mice, and Ms. A. Saito and Ms. R. Harada for their secretarial assis-gated according to their forward and side scatter profiles.
tance. This work was supported by a Grant-in-Aid from the Ministry
of Education, Science, and Culture of Japan.Western Blot Analysis
Splenic T cells, which were sorted by using anti-B220, anti-Gr1, and
anti-Mac1 Ab mAbs (Miltenyi Biotec, Bergisch Gladbach, Germany), Received November 7, 2000; revised March 29, 2001.
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